Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bushenqiangduqinghuatang is a Traditional Chinese Medicine (TCM) herbal decoction developed by the China-Japan Friendship Hospital for the treatment of ankylosing spondylitis (AS). The formula is designed based on TCM principles to tonify the kidney, strengthen the Du meridian, and clear damp-heat, addressing the core pathogenesis of AS in TCM theory. It is currently being evaluated in randomized controlled clinical trials to assess its clinical efficacy and safety, with a specific focus on its ability to inhibit pathological new bone formation, a hallmark of AS progression. The study utilizes serum biochemical markers of new bone formation to provide a scientific basis for its therapeutic effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bushenqiangduqinghuatang.